NASDAQ · DNLI
Healthcare · Biotechnology
$24.92
Down-$0.03 (-0.12%)
Updated Aug 22, 2026, 9:00 AM
SID Score
6.8/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 21 trading sessions · Daily adjusted prices
DNLI closed at $24.92 after 21 trading sessions, up 7.83% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 21, 2026 | $25.25 | $25.37 | $24.60 | $24.92 | 680.99K |
| Aug 20, 2026 | $25.15 | $25.6031 | $24.65 | $24.95 | 976.85K |
| Aug 19, 2026 | $25.00 | $25.70 | $24.61 | $25.69 | 1.15M |
| Aug 18, 2026 | $24.17 | $24.49 | $24.01 | $24.31 | 1.1M |
| Aug 17, 2026 | $24.29 | $24.66 | $24.11 | $24.35 | 1M |
| Aug 14, 2026 | $24.53 | $24.62 | $24.115 | $24.40 | 890K |
| Aug 13, 2026 | $25.24 | $25.64 | $24.81 | $24.82 | 1.35M |
| Aug 12, 2026 | $24.51 | $25.34 | $24.20 | $25.27 | 1.44M |
| Aug 11, 2026 | $25.07 | $25.29 | $24.59 | $24.69 | 1.15M |
| Aug 10, 2026 | $24.71 | $25.035 | $24.21 | $25.00 | 1.56M |
| Aug 7, 2026 | $25.41 | $25.74 | $24.235 | $24.83 | 1.75M |
| Aug 6, 2026 | $24.48 | $24.99 | $24.37 | $24.73 | 3.05M |
| Aug 5, 2026 | $24.29 | $24.55 | $23.96 | $24.42 | 1.09M |
| Aug 4, 2026 | $23.55 | $24.30 | $23.23 | $24.17 | 993.77K |
| Aug 3, 2026 | $22.85 | $23.50 | $22.6275 | $23.15 | 1.48M |
| Jul 31, 2026 | $24.34 | $24.35 | $22.99 | $23.02 | 1.23M |
| Jul 30, 2026 | $23.83 | $24.68 | $23.785 | $24.35 | 1.12M |
| Jul 29, 2026 | $24.20 | $24.3864 | $23.61 | $23.85 | 1.38M |
| Jul 28, 2026 | $23.92 | $24.055 | $23.15 | $24.05 | 2.11M |
| Jul 27, 2026 | $23.59 | $24.17 | $23.44 | $23.57 | 1.75M |
| Jul 24, 2026 | $23.52 | $23.65 | $22.64 | $23.11 | 1.16M |
The latest Smart Investors Daily articles mentioning DNLI.
DNLI research
Company profile and research snapshot.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 7, 2026 | UBS | Buy | — |
| Jul 23, 2026 | Morgan Stanley | Overweight | — |
| Jul 16, 2026 | Deutsche Bank | Buy | — |
| Jul 13, 2026 | JP Morgan | Overweight | — |
| May 26, 2026 | Morgan Stanley | Overweight | — |
No generated briefing is available yet.
Benzinga · Jul 23, 2026
Morgan Stanley analyst Matthew Harrison maintains Denali Therapeutics (NASDAQ:DNLI) with a Overweight and raises the price target from $35 to $36.
SeekingAlpha · Mar 6, 2026
Benzinga · Mar 2, 2026
BTIG analyst Thomas Shrader maintains Denali Therapeutics (NASDAQ:DNLI) with a Buy and raises the price target from $32 to $36.
Yahoo · Feb 26, 2026
Tividenofusp alfa (DNL310; ETV:IDS) launch readiness established ahead of April 5, 2026 Prescription Drug User Fee Act (PDUFA) target action date for Hunter syndromeDNL126 (ETV:SGSH) Phase 1/2 preliminary data presented at 2026 WORLDSymposium™, supporting plans to pursue an accelerated approval path in Sanfilippo syndrome type AStart-up activities underway for DNL628 (OTV:MAPT) Phase 1b study for Alzheimer's disease and DNL952 (ETV:GAA) Phase 1 study for late-onset Pompe diseaseTransportVehicle™
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning DNLI.
